Your browser doesn't support javascript.
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.
Zullo, Lodovica; Rossi, Giovanni; Dellepiane, Chiara; Tagliamento, Marco; Alama, Angela; Coco, Simona; Longo, Luca; Pronzato, Paolo; Maria, Andrea De; Genova, Carlo.
  • Zullo L; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Rossi G; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Dellepiane C; Department of Medical, Surgical & Experimental Sciences, Università degli Studi di Sassari, 07100 Sassari, Italy.
  • Tagliamento M; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Alama A; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Coco S; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Longo L; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Pronzato P; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Maria A; UO Oncologia Medica 2; IRCCS Ospedale Policlinico San Martino, 16100 Genoa, Italy.
  • Genova C; UO Clinica di Malattie Infettive e Tropicali; IRCCS Ospedale Policlinico San Martino, 16100 Genova, Italy.
Immunotherapy ; 13(6): 509-525, 2021 04.
Article in English | MEDLINE | ID: covidwho-1102464
Semantic information from SemMedBD (by NLM)
1. Immune Checkpoint Inhibitors ASSOCIATED_WITH Non-Small Cell Lung Carcinoma
Subject
Immune Checkpoint Inhibitors
Predicate
ASSOCIATED_WITH
Object
Non-Small Cell Lung Carcinoma
2. Immune Checkpoint Inhibitors TREATS Non-Small Cell Lung Carcinoma
Subject
Immune Checkpoint Inhibitors
Predicate
TREATS
Object
Non-Small Cell Lung Carcinoma
3. Frail PROCESS_OF Patients
Subject
Frail
Predicate
PROCESS_OF
Object
Patients
4. Pharmaceutical Preparations ADMINISTERED_TO Patients
Subject
Pharmaceutical Preparations
Predicate
ADMINISTERED_TO
Object
Patients
5. Chronic infectious disease PROCESS_OF Patients
Subject
Chronic infectious disease
Predicate
PROCESS_OF
Object
Patients
6. Poor Performance Status PROCESS_OF Persons
Subject
Poor Performance Status
Predicate
PROCESS_OF
Object
Persons
7. Malignant neoplasm of lung PROCESS_OF Patients
Subject
Malignant neoplasm of lung
Predicate
PROCESS_OF
Object
Patients
8. Problem PROCESS_OF Patients
Subject
Problem
Predicate
PROCESS_OF
Object
Patients
9. Immune Checkpoint Inhibitors ASSOCIATED_WITH Non-Small Cell Lung Carcinoma
Subject
Immune Checkpoint Inhibitors
Predicate
ASSOCIATED_WITH
Object
Non-Small Cell Lung Carcinoma
10. Immune Checkpoint Inhibitors TREATS Non-Small Cell Lung Carcinoma
Subject
Immune Checkpoint Inhibitors
Predicate
TREATS
Object
Non-Small Cell Lung Carcinoma
11. Frail PROCESS_OF Patients
Subject
Frail
Predicate
PROCESS_OF
Object
Patients
12. Pharmaceutical Preparations ADMINISTERED_TO Patients
Subject
Pharmaceutical Preparations
Predicate
ADMINISTERED_TO
Object
Patients
13. Chronic infectious disease PROCESS_OF Patients
Subject
Chronic infectious disease
Predicate
PROCESS_OF
Object
Patients
14. Poor Performance Status PROCESS_OF Persons
Subject
Poor Performance Status
Predicate
PROCESS_OF
Object
Persons
15. Malignant neoplasm of lung PROCESS_OF Patients
Subject
Malignant neoplasm of lung
Predicate
PROCESS_OF
Object
Patients
16. Problem PROCESS_OF Patients
Subject
Problem
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
In recent years, immune-checkpoint inhibitors (ICIs) have represented one of the major breakthroughs in advanced non-small cell lung cancer treatment scenario. However, enrollment in registering clinical trials is usually restricted, since frail patients (i.e., elderly, individuals with poor performance status and/or active brain metastases), as well as patients with chronic infections or who take concurrent medications, such as steroids, are routinely excluded. Thus, safety and efficacy of ICIs for these subgroups have not been adequately assessed in clinical trials, although these populations often occur in clinical practice. We reviewed the available data regarding the use of ICIs in these 'special' populations, including a focus on the issues raised by the administration of immunotherapy in lung cancer patients infected with Sars-Cov-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Vulnerable Populations / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Controlled clinical trial / Randomized controlled trials Limits: Humans Language: English Journal: Immunotherapy Journal subject: Allergy and Immunology / Therapeutics Year: 2021 Document Type: Article Affiliation country: Imt-2020-0226

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Vulnerable Populations / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Controlled clinical trial / Randomized controlled trials Limits: Humans Language: English Journal: Immunotherapy Journal subject: Allergy and Immunology / Therapeutics Year: 2021 Document Type: Article Affiliation country: Imt-2020-0226